Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune SA stock logo
ACIU
AC Immune
$2.31
-1.7%
$2.89
$1.90
$5.14
$228.46M1.05166,629 shs1,890 shs
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
$3.95
+0.3%
$3.73
$1.42
$11.97
$234.69M1.45549,453 shs19,518 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$14.27
+1.9%
$15.74
$7.58
$21.44
$183.80M1.5543,529 shs1,125 shs
Vaccitech plc stock logo
VACC
Vaccitech
$2.27
$2.64
$1.64
$5.10
$87.50M-0.4244,643 shs4,606 shs
Verastem, Inc. stock logo
VSTM
Verastem
$11.74
-1.5%
$11.17
$4.68
$15.18
$297.12M0.58131,210 shs4,127 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune SA stock logo
ACIU
AC Immune
0.00%-3.69%-16.07%-13.28%+11.90%
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-3.19%-6.41%-11.06%+19.39%-61.49%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+2.49%+0.14%-15.75%+65.80%+27.83%
Vaccitech plc stock logo
VACC
Vaccitech
0.00%+3.18%-31.00%-10.84%-1.73%
Verastem, Inc. stock logo
VSTM
Verastem
+4.56%+15.06%+1.53%-9.83%+133.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune SA stock logo
ACIU
AC Immune
2.8287 of 5 stars
3.54.00.00.03.40.80.6
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
1.7252 of 5 stars
3.52.00.00.02.02.50.0
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.679 of 5 stars
3.53.00.00.00.03.30.0
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
2.1644 of 5 stars
3.52.00.00.01.82.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune SA stock logo
ACIU
AC Immune
3.00
Buy$16.00592.64% Upside
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
3.00
Buy$9.33136.29% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$36.00152.28% Upside
Vaccitech plc stock logo
VACC
Vaccitech
2.50
Moderate Buy$7.63235.90% Upside
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$28.79145.19% Upside

Current Analyst Ratings

Latest VACC, VSTM, GLSI, ALDX, and ACIU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/6/2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
4/3/2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$10.00
4/2/2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/19/2024
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.50
3/15/2024
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
3/15/2024
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$32.00
2/28/2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
2/20/2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $36.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune SA stock logo
ACIU
AC Immune
$14.80M15.44N/AN/A$2.12 per share1.09
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$2.04 per shareN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
Vaccitech plc stock logo
VACC
Vaccitech
$13.42M6.52$0.12 per share19.30$6.52 per share0.35
Verastem, Inc. stock logo
VSTM
Verastem
$2.60M114.28N/AN/A$2.27 per share5.17

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune SA stock logo
ACIU
AC Immune
-$60.41M-$0.71N/AN/AN/AN/A-37.51%-33.32%5/10/2024 (Estimated)
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-$37.54M-$0.51N/AN/AN/AN/A-24.69%-20.26%8/1/2024 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$0.70N/AN/AN/A-93.88%-91.17%5/27/2024 (Estimated)
Vaccitech plc stock logo
VACC
Vaccitech
$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/A
Verastem, Inc. stock logo
VSTM
Verastem
-$87.37M-$4.10N/AN/AN/AN/A-127.00%-54.73%8/13/2024 (Estimated)

Latest VACC, VSTM, GLSI, ALDX, and ACIU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/15/2024Q4 2023
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A-$0.21-$0.21-$0.21N/AN/A
3/14/2024Q4 2023
AC Immune SA stock logo
ACIU
AC Immune
-$0.07-$0.06+$0.01-$0.06$16.36 million$16.71 million
3/14/2024Q4 2023
Verastem, Inc. stock logo
VSTM
Verastem
-$0.82-$1.02-$0.20-$1.02N/AN/A
3/7/2024Q4 2023
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-$0.21-$0.08+$0.13-$0.08N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune SA stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune SA stock logo
ACIU
AC Immune
N/A
9.22
9.22
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/A
6.50
6.50
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
23.77
23.77
Vaccitech plc stock logo
VACC
Vaccitech
N/A
15.26
15.26
Verastem, Inc. stock logo
VSTM
Verastem
0.70
5.45
5.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AC Immune SA stock logo
ACIU
AC Immune
51.36%
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
59.71%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Vaccitech plc stock logo
VACC
Vaccitech
26.13%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
AC Immune SA stock logo
ACIU
AC Immune
4.60%
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
7.30%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
52.86%
Vaccitech plc stock logo
VACC
Vaccitech
6.00%
Verastem, Inc. stock logo
VSTM
Verastem
2.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune SA stock logo
ACIU
AC Immune
13398.90 million94.35 millionOptionable
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
1559.41 million55.08 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
312.88 million6.07 millionNot Optionable
Vaccitech plc stock logo
VACC
Vaccitech
3338.55 million36.23 millionNot Optionable
Verastem, Inc. stock logo
VSTM
Verastem
7325.31 million24.75 millionOptionable

VACC, VSTM, GLSI, ALDX, and ACIU Headlines

SourceHeadline
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
investorplace.com - May 10 at 12:09 AM
Arrowhead Research: Fiscal Q2 Earnings SnapshotArrowhead Research: Fiscal Q2 Earnings Snapshot
washingtonpost.com - May 9 at 5:25 PM
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesVerastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
businesswire.com - May 9 at 4:02 PM
Verastem (NASDAQ:VSTM) Stock Price Crosses Above Two Hundred Day Moving Average of $9.80Verastem (NASDAQ:VSTM) Stock Price Crosses Above Two Hundred Day Moving Average of $9.80
americanbankingnews.com - May 9 at 5:02 AM
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceVerastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
businesswire.com - May 7 at 7:30 AM
Verastem Oncology appoints new CMO to lead cancer drug trialsVerastem Oncology appoints new CMO to lead cancer drug trials
investing.com - April 20 at 11:47 PM
Verastem, Inc. (VSTM)Verastem, Inc. (VSTM)
finance.yahoo.com - April 19 at 8:05 PM
Verastem Oncology Names John Hayslip as Chief Medical OfficerVerastem Oncology Names John Hayslip as Chief Medical Officer
marketwatch.com - April 18 at 7:05 PM
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
businesswire.com - April 18 at 4:05 PM
Verastem gets grant for dual RAF/MEK inhibitor for cancer treatment in solid formVerastem gets grant for dual RAF/MEK inhibitor for cancer treatment in solid form
pharmaceutical-technology.com - April 18 at 9:04 AM
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
markets.businessinsider.com - April 12 at 5:19 PM
Verastem (NASDAQ:VSTM) Share Price Passes Above 200-Day Moving Average of $9.47Verastem (NASDAQ:VSTM) Share Price Passes Above 200-Day Moving Average of $9.47
marketbeat.com - April 12 at 2:18 AM
Verastem CFO sells shares to cover tax obligationsVerastem CFO sells shares to cover tax obligations
investing.com - April 10 at 1:47 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com - April 4 at 7:30 AM
Verastem’s Strategic Advancements and Financial Stability Underscore Buy RatingVerastem’s Strategic Advancements and Financial Stability Underscore Buy Rating
markets.businessinsider.com - March 27 at 7:36 PM
Verastem director sells over $8,500 in company stockVerastem director sells over $8,500 in company stock
investing.com - March 22 at 8:04 PM
VSTM Apr 2024 11.000 callVSTM Apr 2024 11.000 call
finance.yahoo.com - March 20 at 4:57 AM
Verastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term LossesVerastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term Losses
markets.businessinsider.com - March 19 at 1:14 PM
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
businesswire.com - March 18 at 7:00 AM
VSTM Apr 2024 14.000 callVSTM Apr 2024 14.000 call
finance.yahoo.com - March 16 at 8:52 AM
Recap: Verastem Q4 EarningsRecap: Verastem Q4 Earnings
benzinga.com - March 14 at 10:18 PM
VSTM Stock Earnings: Verastem Misses EPS for Q4 2023VSTM Stock Earnings: Verastem Misses EPS for Q4 2023
investorplace.com - March 14 at 10:04 PM
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
businesswire.com - March 14 at 4:05 PM
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
finance.yahoo.com - March 11 at 8:25 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AC Immune logo

AC Immune

NASDAQ:ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Aldeyra Therapeutics logo

Aldeyra Therapeutics

NASDAQ:ALDX
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Greenwich LifeSciences logo

Greenwich LifeSciences

NASDAQ:GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Vaccitech logo

Vaccitech

NASDAQ:VACC
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Verastem logo

Verastem

NASDAQ:VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.